The RUSNANO Portfolio Company Bebig Has Started Production of Microsources for the Treatment of Prostate Cancer
OREANDA-NEWS. April 06, 2015. Bebig LLC, a portfolio company of RUSNANO, has launched
The project is a joint venture between the European group of companies Eckert & Ziegler BEBIG and RUSNANO. Total investments in the project amounted to 688 million rubles, including RUSNANO
Brachytherapy is a modern
Prostate cancer is currently one of the most common forms of cancer among Russian men: about 14,000 Russian males are diagnosed with the disease each year and mortality in the first year after diagnosis is 10.3%. Brachytherapy represents a less damaging alternative to surgery and external radiation for patients with first- and
Brachytherapy has become a widely used therapy in many countries during recent years, being successfully applied in 800 medical centers in the U.S. and Western Europe. But it is still far from being generally applied in Russia.
The RUSNANO project promotes import substitution in the field of
Microsources are titanium capsules, which provide excellent biocompatibility and ultrasound imaging. The capsule contains a gold filament, which acts as an
Комментарии